β-Hydroxybutyrate Mitigated Heart Failure with Preserved Ejection Fraction by Increasing Treg Cells via Nox2/GSK-3β

Background: This study was designed to investigate the cardioprotective role of beta-hydroxybutyrate (BHB) in heart failure with preserved ejection fraction (HFpEF) and the underlying mechanism. Methods: A two-hit model with a high-fat diet (HFD) and N.-nitrol-arginine methyl ester (L-NAME) was used as an HFpEF model. The treatment group received a weekly intraperitoneal injection of beta-hydroxybutyrate (BHB). Cardiac function, inflammation, and fibrosis were evaluated. CD3(+)CD4(+)Foxp3(+) positive cells within the myocardium were quantified by flow cytometry. The NADPH oxidase 2 (NOX2)/glycogen synthase kinase-3 beta (GSK3 beta) pathway was examined by immunoblot analysis. Results: BHB improved diastolic function, fibrosis and cardiac remodeling in HFpEF. Additionally, BHB inhibited cardiac inflammation and increased cardiac Treg cells, which could be due to the downregulation of the NOX2/GSK-3 beta pathway. Conclusion: BHB protected against the progression of HFpEF by increasing cardiac Treg cells by modulating the NOX2/GSK-3 beta pathway.

Automated summary

BHB protected against the progression of HFpEF by increasing cardiac Treg cells via modulation of the NOX2/GSK-3 beta pathway, improving diastolic function, fibrosis, and cardiac remodeling in HFpEF.